Abstract Hepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV–HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing antibodies against HCV in vitro. Here, we aimed to increase the neutralizing potential of those antibodies, by using HBV–HCV SVPs bearing apolipoprotein E (apoE). These particles were produced by cultured stable mammalian cell clones, purified and characterized. We found that apoE was able to interact with both chimeric HBV–HCV (E1-S and E2-S) proteins, and with the wild-type HBV S protein. ApoE was also detected on the surface of purified SVPs and i...
Hepatitis C virus (HCV) evades humoral immunity and establishes chronic infections. Virus particles ...
Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disea...
Hepatitis B virus (HBV) is a common cause of liver diseases, including chronic hepatitis, steatosis,...
International audienceAbstract Hepatitis C is a major threat to public health for which an effective...
International audienceThe development of a prophylactic vaccine against hepatitis C virus (HCV) has ...
BACKGROUND & AIMS: Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been...
BACKGROUND & AIMS: Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been...
International audienceVarious strategies involving the use of hepatitis C virus (HCV) E1 and E2 enve...
International audienceThe development of an effective, affordable prophylactic vaccine against hepat...
International audienceThe hepatitis B virus (HBV) envelope protein (S) self-assembles into subviral ...
The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly neutralizing antibodie...
Our previous studies have found that hepatitis C virus (HCV) particles are enriched in apolipoprotei...
Hepatitis C virus (HCV) represents a major global health challenge and an efficient vaccine is urgen...
<div><p>The envelope protein (E1–E2) of Hepatitis C virus (HCV) is a major component of the viral st...
Hepatitis C virus (HCV) evades humoral immunity and establishes chronic infections. Virus particles ...
Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disea...
Hepatitis B virus (HBV) is a common cause of liver diseases, including chronic hepatitis, steatosis,...
International audienceAbstract Hepatitis C is a major threat to public health for which an effective...
International audienceThe development of a prophylactic vaccine against hepatitis C virus (HCV) has ...
BACKGROUND & AIMS: Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been...
BACKGROUND & AIMS: Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been...
International audienceVarious strategies involving the use of hepatitis C virus (HCV) E1 and E2 enve...
International audienceThe development of an effective, affordable prophylactic vaccine against hepat...
International audienceThe hepatitis B virus (HBV) envelope protein (S) self-assembles into subviral ...
The E2 glycoprotein of hepatitis C virus (HCV) is the major target of broadly neutralizing antibodie...
Our previous studies have found that hepatitis C virus (HCV) particles are enriched in apolipoprotei...
Hepatitis C virus (HCV) represents a major global health challenge and an efficient vaccine is urgen...
<div><p>The envelope protein (E1–E2) of Hepatitis C virus (HCV) is a major component of the viral st...
Hepatitis C virus (HCV) evades humoral immunity and establishes chronic infections. Virus particles ...
Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disea...
Hepatitis B virus (HBV) is a common cause of liver diseases, including chronic hepatitis, steatosis,...